FDA Approves Merck’s GRASTEK® (Timothy Grass Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Grass Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Children and Adults

[Business Wire] – Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved GRASTEK® Tablet for Sublingual Use [2800 Bioequivalent Allergy Units ]. more

View todays social media effects on MRK

View the latest stocks trending across Twitter. Click to view dashboard

See who Merck is hiring next, click here to view